Structure-based design of novel human Pin1 inhibitors (III): optimizing affinity beyond the phosphate recognition pocket
- Bioorg Med Chem Lett. 2014 Sep 1;24(17):4187-91. doi: 10.1016/j.bmcl.2014.07.044.
- 1. Oncology Medicinal Chemistry, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA. Electronic address: [email protected].
- 2. Oncology Medicinal Chemistry, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA.
- 3. Oncology Research Unit, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA.
- 4. Pharmacokinetics and Drug Metabolism, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA.
- 5. Oncology Research Unit, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA. Electronic address: [email protected].
The design of potent PIN1 inhibitors has been challenging because its active site specifically recognizes a phospho-protein epitope. The de novo design of phosphate-based PIN1 inhibitors focusing on the phosphate recognition pocket and the successful replacement of the phosphate group with a carboxylate have been previously reported. The potency of the carboxylate series is now further improved through structure-based optimization of ligand-protein interactions in the proline binding site which exploits the H-bond interactions necessary for PIN1 catalytic function. Further optimization using a focused library approach led to the discovery of low nanomolar non-phosphate small molecular PIN1 inhibitors. Structural modifications designed to improve cell permeability resulted in PIN1 inhibitors with low micromolar anti-proliferative activities against Cancer cells.
-
Cat. No.Product NameDescriptionTargetResearch Area
-